| Bioactivity | Fosravuconazole (BMS-379224), a prodrug of Ravuconazole, is an orally active broad spectrum antifungal agent. Fosravuconazole can be used for candidiasis, onychomycosis and parasitemia research[1][2][3]. | ||||||||||||
| Target | Fungal | ||||||||||||
| Invitro | Ravuconazole has potent in vitro antifungal activity against a wide range of fungal species, including Candida, Aspergillus, and Trichophyton species[1]. | ||||||||||||
| In Vivo | Fosravuconazole (E-1224; 10-50 mg/kg; oral administration; daily; for 20 days) treatment suppresses the parasitemia and prevents death in mice infected with the T. cruzi Y strain[3]. Animal Model: | ||||||||||||
| Name | Fosravuconazole | ||||||||||||
| CAS | 351227-64-0 | ||||||||||||
| Formula | C23H20F2N5O5PS | ||||||||||||
| Molar Mass | 547.47 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Shinichi Watanabe, et al. Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study. J Dermatol. 2018 Oct;45(10):1151-1159. [2]. Katsura Hata, et al. Development of E1224 by leveraging a strategic partnership for the medicines creation against neglected tropical diseases. Parasitol Int. 2020 Dec 25;81:102278. [3]. Lívia de Figueiredo Diniz, et al. Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice. Antimicrob Agents Chemother. 2018 May 25;62(6):e00401-18. |
Fosravuconazole
CAS: 351227-64-0 F: C23H20F2N5O5PS W: 547.47
Fosravuconazole (BMS-379224), a prodrug of Ravuconazole, is an orally active broad spectrum antifungal agent. Fosravucon
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.